// App-Quantinova.ai

3532 : Efficacy of PRT060318, a Novel Highly Specific SYK Inhibitor, in Acute Lymphoblastic Leukemia (ALL)

Researchers

Presenter

  • Greg Coffey

Principal Investigators

  • Ekaterina Kim

  • Deborah Thomas

  • Hagop M Kantarjian

  • Jan A. Burger

  • Nathalie Y Rosin

  • Uma Sinha

  • Anjali Pandey

  • Medhat Shehata

  • Ulrich Jager

  • Susan M. O'Brien

  • William G. Wierda

  • Zeev Estrov

Medical Centers

  • Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX, Houston, TX

  • Department for Medicine I/Clinical Division of Oncology, Medical University of Vienna, Vienna, Austria

Locations

  • United States

  • Austria

Companies

  • Portola Pharmaceutic

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

  • Chronic Lymphocytic Leukemia

  • B-cell acute lymphoblastic leukemia

  • Diffuse large B-cell lymphoma

Biomarkers

  • Spleen tyrosine kinase

Drug/Treatment

  • PRT060318

  • L-Tyrosine

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved